Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | PGR | P06401 | 6/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | AR | P10275 | 4/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934288 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1LMNAPGR | |
| SCHEMBL3046233 | 0.84 | PGR (0.59) | MEN1KMT2ATDP1LMNAPGR | |
| SCHEMBL11515102 | 0.83 | MEN1 (0.54) | MEN1KMT2ATDP1LMNAPGR | |
| SCHEMBL5925193 | 0.83 | PGR (0.70) | MEN1KMT2ATDP1LMNAPGR | |
| SCHEMBL149089 | 0.83 | PGR (0.70) | MEN1KMT2ATDP1LMNAPGR | |
| Melengestrol Acetate SCHEMBL4520 | 0.83 | LMNA (1.00) | MEN1KMT2ATDP1LMNAPGR | |
| Melengestrol Acetate SCHEMBL15079259 | 0.83 | LMNA (1.00) | MEN1KMT2ATDP1LMNAPGR | |
| Melengestrol Acetate SCHEMBL10867312 | 0.83 | LMNA (1.00) | MEN1KMT2ATDP1LMNAPGR | |
| Melengestrol Acetate SCHEMBL16389279 | 0.83 | LMNA (1.00) | MEN1KMT2ATDP1LMNAPGR | |
| Melengestrol Acetate SCHEMBL13778228 | 0.83 | LMNA (1.00) | MEN1KMT2ATDP1LMNAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101360832-B | Process for the preparation of 11 beta-hydroxy-9 beta, 10 alpha-steroids using cells of amycolatopsis mediterranei | SOLVAY PHARMACEUTICALS B.V. (DE) | 2011-12-07 | — | — | CN | disclosed |
| EP-1976997-B1 | PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA,10ALPHA-STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS | SOLVAY PHARM GMBH (DE) | 2009-04-08 | — | — | EP | disclosed |
| CN-101360832-A | Process for the preparation of 11 beta-hydroxy-9 beta, 10 alpha-steroids using cells of amycolatopsis mediterranei | SOLVAY PHARM GMBH (DE) | 2009-02-04 | — | — | CN | disclosed |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| EP-1976997-A1 | PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA, 10ALPHA -STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS | Solvay Pharmaceuticals GmbH (DE) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008113851-A2 | NOVEL C11 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| CN-101258159-A | Novel c18 modified retrosteroids as progesterone receptor modulator compounds | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | CN | disclosed |
| EP-1928894-A1 | NOVEL C18 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | Solvay Pharmaceuticals GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20070212751-A1 | Microbial method for the 11beta hydroxylation of 9beta, 10alpha-steriods | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| WO-2007082891-A1 | PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA, 10ALPHA -STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007039544-A1 | NOVEL C18 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070082876-A1 | Novel C18 modified retrosteroids as progesterone receptor modulator compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | MEN1 639/4885KMT2A 2742/4885TDP1 3457/4885 |
| US-20070082876-A1 | Novel C18 modified retrosteroids as progesterone receptor modulator compounds | HSD17B11, CYP19A1, CYP17A1 | MEN1 2301/4885KMT2A 1643/4885TDP1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.